Skip to main content

4D Molecular Therapeutics, Inc. (FDMT) research

4D Molecular Therapeutics, Inc.
ShareXLinkedInReddit
Sector
Biotechnology
Last price
$15.24
As of

4D Molecular Therapeutics, Inc. (FDMT): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-13.

As of . Source: SEC EDGAR filings for FDMT. Method and limitations.

SHARE THIS CARD

Share the FDMT intelligence card

A branded snapshot of FDMT: the smart money composite, cross family confluence, and the top current signal, with a link back to this page. Post it, download it, or embed it anywhere.

Kresmion FDMT intelligence card preview
Post to X
LIVE TERMINAL

See FDMT live in the terminal

Track FDMT's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.

Open the live FDMT terminal, free

Active signals for FDMT

FREE, NO ACCOUNT

Every signal on FDMT, as it fires

You are seeing 5 of 13 signals recorded on FDMT since 2026-06-10.

The five above landed across 2 days. The other 8 were recorded on 2 other days. 10 of the 13 are institutional flow rows, which arrive in batches on filing days.

Get it by email

No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.

Join on Telegram
Join on Telegram

One tap. Live alerts, no email needed.

Largest reported share positions in FDMT (2026Q2)

Manager / securityMarket value% portfolioQoQ
CITADEL ADVISORS LLCCUSIP 35104E100 · 2026Q2$9.1M0.00%,
RENAISSANCE TECHNOLOGIES LLCCUSIP 35104E100 · 2026Q2$8.2M0.01%,
TWO SIGMA INVESTMENTS, LPCUSIP 35104E100 · 2026Q2$924K0.00%,
D. E. Shaw & Co., Inc.CUSIP 35104E100 · 2026Q2$590K0.00%,

Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.

Recent SEC filings, FDMT

FDMT against its peers

FDMT's operating margin of -187.2% ranks in the 35th percentile of 12 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.

MetricFDMTPeer medianPercentilen
Revenue FY85.2M USD76.2M USD5413
Operating margin-187.2%-44.2%3512
Net margin-164.4%-19.0%3512
Return on equity-27.7%-37.1%7222

Peers (23): WVE, OLMA, ACHV, RIGL, GERN, ARDX, GYRE, TBPH, CLYM, IMMX, ANNX, DBVT, SGP, AVTX, PHAR, SANA, DSGN, SLN, CADL, SLDB, ZVRA, CTMX, LXRX. Left out: ETRA (no annual filing), IVA (period gap). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (FDMT: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.

Related tickers

See more FDMT signals as they fire

Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to FDMTand get the insider, 13F, options, and confluence read in one view.

Open the live FDMT terminal, free